A @entity1 with unresectable advanced @entity788 achieving long-term survival with XXXX chemotherapy.

@entity1 @entity788 @entity1087 @entity5 @entity409 @entity136 @entity3 @entity420
A 68-year-old female visited a local clinic with epigastralgia. A routine laboratory test revealed @entity1087 and @entity409 . She was referred to this hospital. Abdominal computed tomography (CT) and endoscopic retrograde cholangio-pancreatography (ERCP) revealed that the density of the entire pancreas had decreased, and showed dilatation of the common bile duct (CBD) and the main pancreatic duct (MPD). @entity788 was diagnosed by cytological examination analyzing the pancreatic juice obtained by ERCP. When @entity1087 had @entity5 was observed via laparotomy. No ascites, liver @entity3 , or peritoneal dissemination was observed. The entire pancreas was a hard mass, and a needle biopsy was obtained from the head, body and tail of the pancreas. These biopsies diagnosed a poorly differentiated @entity420 . Hepaticojejunostomy was thus performed, and postoperative progress was good. Chemotherapy with 1000 mg/body per week of @entity136 was administered beginning 15 d postoperatively. However, the @entity1 suffered relatively severe side effects, and it was necessary to change the dosing schedule of @entity136 . Abdominal CT revealed a complete response (CR) after 3 treatments. Therefore, weekly chemotherapy was stopped and was changed to monthly administration. To date, for 4 years after chemotherapy, the @entity5 has not reappeared.
